The University of Southampton
University of Southampton Institutional Repository

Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial

Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial
Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial

Objectives: persistently impaired culprit artery flow (<TIMI 3) during primary percutaneous coronary intervention is a surrogate for failed myocardial perfusion. We evaluated the effects of intracoronary alteplase according to TIMI flow grade immediately preceding drug administration. 

Methods: in T-TIME (trial of low-dose adjunctive alTeplase during primary PCI), patients ≤6 hours from onset of ST-elevation myocardial infarction (STEMI) were randomised to placebo, alteplase 10 mg or alteplase 20 mg, administered by infusion into the culprit artery, pre-stenting. In this prespecified, secondary analysis, coronary flow was assessed angiographically at the point immediately before drug administration. Microvascular obstruction, myocardial haemorrhage and infarct size were assessed by cardiovascular magnetic resonance (CMR) at 2-7 days and 3 months. 

Results: TIMI flow was assessed after first treatment (balloon angioplasty/aspiration thrombectomy), immediately pre-drug administration, in 421 participants (mean age 61±10 years, 85% male) and was 3, 2 or 1 in 267, 134 and 19 participants respectively. In patients with TIMI flow ≤2 pre-drug, there was higher incidence of microvascular obstruction with alteplase (alteplase 20 mg (53.1%) and 10 mg (59.5%) combined versus placebo (34.1%); OR=2.47 (95% CI 1.16 to 5.22, p=0.018) interaction p=0.005) and higher incidence of myocardial haemorrhage (alteplase 20 mg (53.1%) and 10 mg (57.9%) combined vs placebo (27.5%); OR=3.26 (95% CI 1.44 to 7.36, p=0.004) interaction p=0.001). These effects were not observed in participants with TIMI 3 flow pre-drug. There were no interactions between TIMI flow pre-drug, alteplase and 3-month CMR findings. 

Conclusion: in patients with impaired culprit artery flow (<TIMI 3) after initial balloon angioplasty/thrombus aspiration, intracoronary alteplase was associated with increased presence of microvascular obstruction and myocardial haemorrhage. 

Trial registration number: NCT02257294.

acute myocardial infarction
1355-6037
299-312
Maznyczka, Annette Marie
ff0d015c-6342-4eac-9368-ffa9521abbc2
Mccartney, Peter
528e0a77-0da8-4f58-a98c-ef26d008fbb2
Duklas, Patrycja
529867b4-b34e-4bdb-ad96-f7ab871be122
Mcentegart, Margaret
c663c90a-2511-4c90-87eb-0ac05d9ad464
Oldroyd, Keith G.
536fd60e-50d0-4a76-a818-ab6b2b03567f
Greenwood, John P.
af864161-94e9-4094-9c1f-85d696682fb7
Muir, Douglas
ac518ef9-fb4a-43ce-b57d-fb52a929ebd7
Chowdhary, Saqib
dc1f7414-d2b9-448c-b9f2-da9156aac1bf
Gershlick, Anthony H.
5beb7f92-68f7-41df-ba72-ef3d2cdf20b9
Appleby, Clare
bb8e2e92-71fa-4270-9382-f2923f02c2b1
Eteiba, Hany
4f08065f-3547-412a-83c9-3f5b37777745
Cotton, James
2a80a7b9-b59f-49ba-8101-c2746999c20c
Wragg, Andrew
7e403a07-92c2-4063-b8d4-0154a60b4ff8
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Tait, R. Campbell
1162c7f2-55fb-428a-92ec-122dc9ed423e
Macfarlane, Peter
c2cea789-4512-44df-9456-60083d17292e
Welsh, Paul
09de190a-183c-444a-aa04-4b57b4cc81b1
Sattar, Naveed
49fba669-53c0-4cad-a8d7-70f54010d8c2
Petrie, Mark C.
f53b1a39-14d9-41ab-a384-6cc78f32183b
Ford, Ian
9fd64fa3-4f53-4b12-9536-4506f9759585
Fox, Keith A.A.
cb14d631-49e0-4eaa-9c31-bc8fa56bcf62
Mcconnachie, Alex
c930d8cf-ab00-47e9-a22d-dbcf7a26f039
Berry, Colin
106fbcaa-69ba-45ec-969f-6f18e06680cf
et al.
Maznyczka, Annette Marie
ff0d015c-6342-4eac-9368-ffa9521abbc2
Mccartney, Peter
528e0a77-0da8-4f58-a98c-ef26d008fbb2
Duklas, Patrycja
529867b4-b34e-4bdb-ad96-f7ab871be122
Mcentegart, Margaret
c663c90a-2511-4c90-87eb-0ac05d9ad464
Oldroyd, Keith G.
536fd60e-50d0-4a76-a818-ab6b2b03567f
Greenwood, John P.
af864161-94e9-4094-9c1f-85d696682fb7
Muir, Douglas
ac518ef9-fb4a-43ce-b57d-fb52a929ebd7
Chowdhary, Saqib
dc1f7414-d2b9-448c-b9f2-da9156aac1bf
Gershlick, Anthony H.
5beb7f92-68f7-41df-ba72-ef3d2cdf20b9
Appleby, Clare
bb8e2e92-71fa-4270-9382-f2923f02c2b1
Eteiba, Hany
4f08065f-3547-412a-83c9-3f5b37777745
Cotton, James
2a80a7b9-b59f-49ba-8101-c2746999c20c
Wragg, Andrew
7e403a07-92c2-4063-b8d4-0154a60b4ff8
Curzen, Nick
70f3ea49-51b1-418f-8e56-8210aef1abf4
Tait, R. Campbell
1162c7f2-55fb-428a-92ec-122dc9ed423e
Macfarlane, Peter
c2cea789-4512-44df-9456-60083d17292e
Welsh, Paul
09de190a-183c-444a-aa04-4b57b4cc81b1
Sattar, Naveed
49fba669-53c0-4cad-a8d7-70f54010d8c2
Petrie, Mark C.
f53b1a39-14d9-41ab-a384-6cc78f32183b
Ford, Ian
9fd64fa3-4f53-4b12-9536-4506f9759585
Fox, Keith A.A.
cb14d631-49e0-4eaa-9c31-bc8fa56bcf62
Mcconnachie, Alex
c930d8cf-ab00-47e9-a22d-dbcf7a26f039
Berry, Colin
106fbcaa-69ba-45ec-969f-6f18e06680cf

Maznyczka, Annette Marie, Mccartney, Peter and Duklas, Patrycja , et al. (2021) Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 107 (4), 299-312. (doi:10.1136/heartjnl-2020-317828).

Record type: Article

Abstract

Objectives: persistently impaired culprit artery flow (<TIMI 3) during primary percutaneous coronary intervention is a surrogate for failed myocardial perfusion. We evaluated the effects of intracoronary alteplase according to TIMI flow grade immediately preceding drug administration. 

Methods: in T-TIME (trial of low-dose adjunctive alTeplase during primary PCI), patients ≤6 hours from onset of ST-elevation myocardial infarction (STEMI) were randomised to placebo, alteplase 10 mg or alteplase 20 mg, administered by infusion into the culprit artery, pre-stenting. In this prespecified, secondary analysis, coronary flow was assessed angiographically at the point immediately before drug administration. Microvascular obstruction, myocardial haemorrhage and infarct size were assessed by cardiovascular magnetic resonance (CMR) at 2-7 days and 3 months. 

Results: TIMI flow was assessed after first treatment (balloon angioplasty/aspiration thrombectomy), immediately pre-drug administration, in 421 participants (mean age 61±10 years, 85% male) and was 3, 2 or 1 in 267, 134 and 19 participants respectively. In patients with TIMI flow ≤2 pre-drug, there was higher incidence of microvascular obstruction with alteplase (alteplase 20 mg (53.1%) and 10 mg (59.5%) combined versus placebo (34.1%); OR=2.47 (95% CI 1.16 to 5.22, p=0.018) interaction p=0.005) and higher incidence of myocardial haemorrhage (alteplase 20 mg (53.1%) and 10 mg (57.9%) combined vs placebo (27.5%); OR=3.26 (95% CI 1.44 to 7.36, p=0.004) interaction p=0.001). These effects were not observed in participants with TIMI 3 flow pre-drug. There were no interactions between TIMI flow pre-drug, alteplase and 3-month CMR findings. 

Conclusion: in patients with impaired culprit artery flow (<TIMI 3) after initial balloon angioplasty/thrombus aspiration, intracoronary alteplase was associated with increased presence of microvascular obstruction and myocardial haemorrhage. 

Trial registration number: NCT02257294.

This record has no associated files available for download.

More information

Accepted/In Press date: 2 November 2020
e-pub ahead of print date: 12 January 2021
Published date: January 2021
Additional Information: Funding Information: Funding AMM is funded by a fellowship from the British Heart Foundation (FS/16/74/32573). CB is supported by grants from the British Heart Foundation (RE/18/6/34217; FS/16/74/32573). T-TIME was supported by grant 12/170/4 from the Efficacy and Mechanism Evaluation (EME) programme of the National Institute for Health Research (NIHR-EME). Boehringer-Ingelheim UK Ltd provided the study drugs (alteplase 10 mg, 20 mg and matched placebo). The research was in part supported by the National Institute for Health Research infrastructure at Leeds. Funding Information: AMM is funded by a fellowship from the British Heart Foundation (FS/16/74/32573). CB is supported by grants from the British Heart Foundation (RE/18/6/34217; FS/16/74/32573). T-TIME was supported by grant 12/170/4 from the Efficacy and Mechanism Evaluation (EME) programme of the National Institute for Health Research (NIHR-EME). Boehringer-Ingelheim UK Ltd provided the study drugs (alteplase 10 mg, 20 mg and matched placebo). The research was in part supported by the National Institute for Health Research infrastructure at Leeds. Publisher Copyright: © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
Keywords: acute myocardial infarction

Identifiers

Local EPrints ID: 511079
URI: http://eprints.soton.ac.uk/id/eprint/511079
ISSN: 1355-6037
PURE UUID: aaef51fd-4c42-44c7-ab2b-3b53179a7bf7
ORCID for Nick Curzen: ORCID iD orcid.org/0000-0001-9651-7829

Catalogue record

Date deposited: 01 May 2026 16:30
Last modified: 02 May 2026 01:43

Export record

Altmetrics

Contributors

Author: Annette Marie Maznyczka
Author: Peter Mccartney
Author: Patrycja Duklas
Author: Margaret Mcentegart
Author: Keith G. Oldroyd
Author: John P. Greenwood
Author: Douglas Muir
Author: Saqib Chowdhary
Author: Anthony H. Gershlick
Author: Clare Appleby
Author: Hany Eteiba
Author: James Cotton
Author: Andrew Wragg
Author: Nick Curzen ORCID iD
Author: R. Campbell Tait
Author: Peter Macfarlane
Author: Paul Welsh
Author: Naveed Sattar
Author: Mark C. Petrie
Author: Ian Ford
Author: Keith A.A. Fox
Author: Alex Mcconnachie
Author: Colin Berry
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×